Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Risk factors

Topic: Brain proteins, microglia and lab models

Plain-language summary

A total of 60 860 adults with type 2 diabetes and obesity were included, with 30 430 each in the GLP-1RA group (mean [SD] age, 57.9 [9.9] years; 50.2% female) and the other antidiabetic drug group (mean [SD] age, 58.0 [10.8] years; 51.4% female) after propensity score matching. During a 7-year follow-up, GLP-1RA users had a lower risk of dementia (HR, 0.63; 95% CI, 0.50-0.81), stroke (HR, 0.81; 95% CI, 0.70-0.93), and all-cause mortality (HR, 0.70; 95% CI, 0.63-0.78), with no significant differences in the risk of Parkinson disease or intracerebral hemorrhage. Subgroup analyses revealed greater benefits in patients aged 60 years or older, women, and patients with a body mass index of 30 to 40. Conclusions and Relevance: In this cohort study, the use of GLP-1RAs semaglutide and tirzepatide was associated with a lower risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. These findings suggest potential neuroprotective and cerebrovascular benefits of GLP-1RAs beyond glycemic control, warranting further trials to confirm these outcomes.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 860 participants. In this cohort of adults with type 2 diabetes and obesity, those taking the GLP-1 receptor agonists semaglutide or tirzepatide had a lower risk of dementia, stroke and death over 7 years. Reported effect size: 50.2%; 51.4%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lin, H.-T., Tsai, Y., Liao, P., & Wei, J. C.-C. (2025). Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.21016

Vancouver

Lin H.-T, Tsai Y, Liao P, Wei JC.-C. Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.21016. PMID: 40663350.

BibTeX

@article{lin2025-40663350,
  author  = {Lin, Huan-Tang and Tsai, Yung‐Fong and Liao, Pei‐Lun and Wei, James Cheng-Chung},
  title   = {{Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity}},
  journal = {JAMA Network Open},
  year    = {2025},
  doi     = {10.1001/jamanetworkopen.2025.21016},
  pmid    = {40663350},
  url     = {https://doi.org/10.1001/jamanetworkopen.2025.21016}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In this cohort of adults with type 2 diabetes and obesity, those taking the GLP-1 receptor agonists semaglutide or tirzepatide had a lower risk of dementia, stroke and death over 7 years. The authors call for further trials to confirm these potential neuroprotective and cerebrovascular benefits.

Study details

How this study scored 63/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 5 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 63 of 100.63 of 100 points earned37 not earned

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA Network Open)
Journal's citation record 2 / 4 JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 860 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 43 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 14.3 citations a year over 3 year(s) since 2025
Impact for its field and year 5 / 6 Cited 25.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 43 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author James Cheng-Chung Wei: h-index 6 (OpenAlex, whole career)
Institution's track record 0 / 3 Chang Gung Memorial Hospital: institution h-index 424 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40663350)
Free to read 2 / 2 Free to read
Total 63 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk factors from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk factors

See all studies in Risk factors →